Analysis of DNA methylation profiles confirms a high proportion of immune cells in glioblastoma samples

Glioblastomas are malignant tumors that belong to the central nervous system and are challenging to diagnose due to their significant intratumoral heterogeneity, which makes molecular testing and diagnosis confirmation particularly difficult. In addition to identifying typical genetic mutations such as IDH, H3F3A G34 and K27, WHO recommendations emphasize the importance of analyzing the tumor epigenome to define its class based on DNA methylation patterns and methylation status of specific genomic regions, particularly the MGMT promoter region. Based on our clinical experience, molecular genetic studies sometimes yield contradictory results due to the heterogeneous cellular composition of glioblastomas. In this study, we present a series of observations made on 35 glioblastoma samples in which we compare the morphological features and the results of cell type detection by deconvolution method based on total DNA methylation profiles. Our results suggest that samples of mesenchymal class glioblastomas may contain over 50 % non-tumor immune cells, which should be considered in genetic testing of these tumors.

1. Ostrom Q.T., Price M., Neff C., Cioffi G., Waite K.A., Kruchko C., Barnholtz-Sloan J.S. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2015–2019. Neuro Oncol. 2022;24(Suppl 5):v1–v95. doi: 10.1093/neuonc/noac202.

2. Louis D.N., Ohgaki H., Wiestler O.D., Cavenee W.K. World Health Organization Classifi cation of Tumours of the Central Nervous System. 4th ed., updated ed. Lyon: International Agency for Research on Cancer; 2016.

3. WHO Classifi cation of Tumours Editorial Board. World Health Organization Classifi cation of Tumours of the Central Nervous System. 5th ed. Lyon: International Agency for Research on Cancer; 2021.

4. Sturm D., Witt H., Hovestadt V., Khuong-Quang D.A., Jones D.T., Konermann C., Pfaff E., Tönjes M., Sill M., Bender S., Kool M., Zapatka M., Becker N., Zucknick M., Hielscher T., Liu X.Y., Fontebasso A.M., Ryzhova M., Albrecht S., Jacob K., Wolter M., Ebinger M., Schuhmann M.U., van Meter T., Frühwald M.C., Hauch H., Pekrun A., Radlwimmer B., Niehues T., von Komorowski G., Dürken M., Kulozik A.E., Madden J., Donson A., Foreman N.K., Drissi R., Fouladi M., Scheurlen W., von Deimling A., Monoranu C., Roggendorf W., Herold-Mende C., Unterberg A., Kramm C.M., Felsberg J., Hartmann C., Wiestler B., Wick W., Milde T., Witt O., Lindroth A.M., Schwartzentruber J., Faury D., Fleming A., Zakrzewska M., Liberski P.P., Zakrzewski K., Hauser P., Garami M., Klekner A., Bognar L., Morrissy S., Cavalli F., Taylor M.D., van Sluis P., Koster J., Versteeg R., Volckmann R., Mikkelsen T., Aldape K., Reifenberger G., Collins V.P., Majewski J., Korshunov A., Lichter P., Plass C., Jabado N., Pfi ster S.M. Hotspot mutations in H3F3A and IDH1 defi ne distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell. 2012;22(4):425–37. doi: 10.1016/j.ccr.2012.08.024.

5. Capper D., Jones D.T.W., Sill M., Hovestadt V., Schrimpf D., Sturm D., Koelsche C., Sahm F., Chavez L., Reuss D.E., Kratz A., Wefers A.K., Huang K., Pajtler K.W., Schweizer L., Stichel D., Olar A., Engel N.W., Lindenberg K., Harter P.N., Braczynski A.K., Plate K.H., Dohmen H., Garvalov B.K., Coras R., Hölsken A., Hewer E., Bewerunge-Hudler M., Schick M., Fischer R., Beschorner R., Schittenhelm J., Staszewski O., Wani K., Varlet P., Pages M., Temming P., Lohmann D., Selt F., Witt H., Milde T., Witt O., Aronica E., Giangaspero F., Rushing E., Scheurlen W., Geisenberger C., Rodriguez F.J., Becker A., Preusser M., Haberler C., Bjerkvig R., Cryan J., Farrell M., Deckert M., Hench J., Frank S., Serrano J., Kannan K., Tsirigos A., Brück W., Hofer S., Brehmer S., Seiz-Rosenhagen M., Hänggi D., Hans V., Rozsnoki S., Hansford J.R., Kohlhof P., Kristensen B.W., Lechner M., Lopes B., Mawrin C., Ketter R., Kulozik A., Khatib Z., Heppner F., Koch A., Jouvet A., Keohane C., Mühleisen H., Mueller W., Pohl U., Prinz M., Benner A., Zapatka M., Gottardo N.G., Driever P.H., Kramm C.M., Müller H.L., Rutkowski S., von Hoff K., Frühwald M.C., Gnekow A., Fleischhack G., Tippelt S., Calaminus G., Monoranu C.M., Perry A., Jones C., Jacques T.S., Radlwimmer B., Gessi M., Pietsch T., Schramm J., Schackert G., Westphal M., Reifenberger G., Wesseling P., Weller M., Collins V.P., Blümcke I., Bendszus M., Debus J., Huang A., Jabado N., Northcott P.A., Paulus W., Gajjar A., Robinson G.W., Taylor M.D., Jaunmuktane Z., Ryzhova M., Platten M., Unterberg A., Wick W., Karajannis M.A., Mittelbronn M., Acker T., Hartmann C., Aldape K., Schüller U., Buslei R., Lichter P., Kool M., Herold-Mende C., Ellison D.W., Hasselblatt M., Snuderl M., Brandner S., Korshunov A., von Deimling A., Pfi ster S.M. DNA methylation-based classifi cation of central nervous system tumours. Nature. 2018;555(7697):469–74. doi: 10.1038/nature26000.

6. Capper D., Stichel D., Sahm F., Jones D.T.W., Schrimpf D., Sill M., Schmid S., Hovestadt V., Reuss D.E., Koelsche C., Reinhardt A., Wefers A.K., Huang K., Sievers P., Ebrahimi A., Schöler A., Teichmann D., Koch A., Hänggi D., Unterberg A., Platten M., Wick W., Witt O., Milde T., Korshunov A., Pfi ster S.M., von Deimling A. Practical implementation of DNA methylation and copy-number-based CNS tumor diagnostics: the Heidelberg experience. Acta Neuropathol. 2018;136(2):181–210. doi: 10.1007/s00401-018-1879-y.

7. Ryzhova M.V., Galstyan S.A., Telysheva E.N. Signifi cance of DNA methylation assessment in the morphological diagnosis of brain tumours. Arkhiv patologii = Pathology Archive. 2022;84(3):65 75. (In Russ.).

8. Ryzhova M.V., Telysheva E.N., Shaikhaev E.G., Starovoitov D.V., Kotelnikova A.O., Galstyan S.A., Okonechnikov K.V. Current diagnostic methods in molecular classifi cation of brain tumors at the Burdenko Neurosurgical Center. Zhurnal Voprosy Neirokhirurgii Imeni N.N. Burdenko = Burdenko’s Journal of Neurosurgery. 2021;85(6):98–101. (In Russ.).

9. Petrova E.I., Galstyan S.A., Telysheva E.N., Ryzhova M.V. Visualization of DNA methylation profi ling data as a quality control tool for molecular classifi cation of CNS tumors. Rossiyskiy neyrokhirurgicheskiy zhurnal imeni professora A.L. Polenova = Russian Neurosurgical Journal named after prof. A.L. Polenov. 2022;14(4):64–70. (In Russ.).

10. Aryee M.J., Jaff e A.E., Corrada-Bravo H., Ladd-Acosta C., Feinberg A.P., Hansen K.D., Irizarry R.A. Minfi : a fl exible and comprehensive Bioconductor package for the analysis of Infi nium DNA methylation microarrays. Bioinformatics. 2014;30(10):1363–9. doi: 10.1093/bioinformatics/btu049.

11. Mansell G., Gorrie-Stone T.J., Bao Y., Kumari M., Schalkwyk L.S., Mill J., Hannon E. Guidance for DNA methylation studies: statistical insights from the Illumina EPIC array. BMC Genomics. 2019;20(1):366. doi: 10.1186/s12864-019-5761-7.

12. Bady P., Sciuscio D., Diserens A.C., Bloch J., van den Bent M.J., Marosi C., Dietrich P.Y., Weller M., Mariani L., Heppner F.L., Mcdonald D.R., Lacombe D., Stupp R., Delorenzi M., Hegi M.E. MGMT methylation analysis of glioblastoma on the Infi nium methylation BeadChip identifi es two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status. Acta Neuropathol. 2012;124(4):547–60. doi: 10.1007/s00401-012-1016-2. Erratum in: Acta Neuropathol. 2013;126(1):159.

13. Teschendorff A.E., Breeze C.E., Zheng S.C., Beck S. A comparison of reference-based algorithms for correcting cell-type heterogeneity in Epigenome-Wide Association Studies. BMC Bioinformatics. 2017;18(1):105. doi: 10.1186/s12859-017-1511-5.

14. Grabovska Y., Mackay A., O’Hare P., Crosier S., Finetti M., Schwalbe E.C., Pickles J.C., Fairchild A.R., Avery A., Cockle J., Hill R., Lindsey J., Hicks D., Kristiansen M., Chalker J., Anderson J., Hargrave D., Jacques T.S., Straathof K., Bailey S., Jones C., Cliff ord S.C., Williamson D. Pediatric pan-central nervous system tumor analysis of immune-cell infi ltration identifi es correlates of antitumor immunity. Nat Commun. 2020;11(1):4324. doi: 10.1038/s41467-020-18070-y.

15. Chen Z., Hambardzumyan D. Immune Microenvironment in Glioblastoma Subtypes. Front Immunol. 2018;9:1004. doi: 10.3389/fi mmu.2018.01004.

16. Mo F., Pellerino A., Soffi etti R., Rudà R. Blood-Brain Barrier in Brain Tumors: Biology and Clinical Relevance. Int J Mol Sci. 2021;22(23):12654. doi: 10.3390/ijms222312654. 17. Han S., Ma E., Wang X., Yu C., Dong T., Zhan W., Wei X., Liang G., Feng S. Rescuing defective tumor-infi ltrating T-cell proliferation in glioblastoma patients. Oncol Lett. 2016;12(4):2924–9. doi: 10.3892/ol.2016.4944.

17. Zhai L., Ladomersky E., Lauing K.L., Wu M., Genet M., Gritsina G., Győrff y B., Brastianos P.K., Binder D.C., Sosman J.A., Giles F.J., James C.D., Horbinski C., Stupp R., Wainwright D.A. Infi ltrating T Cells Increase IDO1 Expression in Glioblastoma and Contribute to Decreased Patient Survival. Clin Cancer Res. 2017;23(21):6650–60. doi: 10.1158/1078-0432.CCR-17-0120.